Sign In
Buy CYCN
$3.00
-0.0200 (-0.662%)
At Close: Jun 03, 2026
CYCN Stock Price Increases Over 25%: Why It Happened
03:34pm, Thursday, 04'th Feb 2021
The stock price of Cyclerion Therapeutics Inc (NASDAQ: CYCN) is trading at over 25% today as of 3:28 PM ET. This is why it happened.
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
07:00am, Monday, 25'th Jan 2021
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company's advancement of therapeutic pipeline candidates
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C.
07:00am, Monday, 04'th Jan 2021
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious dise
Cyclerion Announces Leadership Transitions
07:30am, Monday, 21'st Dec 2020
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
07:00am, Thursday, 05'th Nov 2020
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative
Washington Business Journal Ranks Intelligent Waves Amongst Largest Veteran-Owned Companies in 2020
12:00am, Tuesday, 25'th Aug 2020
Intelligent Waves LLC, a leading-edge trusted IT systems integrator, that delivers high-impact transformational IT solutions to Government's most miss
Superior Group Looks Like A Winner (NASDAQ:SGC)
04:39pm, Tuesday, 11'th Aug 2020
Superior Group is a winning stock. It's the newest addition to my Quality portfolio.
Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
01:25pm, Monday, 03'rd Aug 2020
- IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively -- Completed $24 million equity private placement to accelerate clinica
Cyclerion Therapeutics Completes $24 Million Private Placement
01:00pm, Thursday, 30'th Jul 2020
- Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease - \- IW-6463 translational pharmacology and olinciguat STRONG Phase
Critical Review: Abeona Therapeutics (NASDAQ:ABEO) versus Cyclerion Therapeutics (NASDAQ:FBRX)
01:06am, Sunday, 19'th Jul 2020
Abeona Therapeutics (NASDAQ:ABEO) and Cyclerion Therapeutics (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the str
Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit
11:00am, Friday, 17'th Jul 2020
CAMBRIDGE, Mass., July 17, 2020 -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan.
China to become "export destination country number one" for Germany: IW
12:54am, Friday, 17'th Jul 2020
BERLIN, July 16 (Xinhua) -- China was on its way to become "export destination country number one" for the German economy as the COVID-19 crisis was hitting global trade, according to a study publishe
We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate
07:17pm, Monday, 06'th Jul 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Should You Buy Cyclerion Therapeutics, Inc. (CYCN)?
06:45pm, Sunday, 05'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
How R&D Expenses Can Help You Pick Outperforming Stocks
12:13pm, Thursday, 02'nd Jul 2020
A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet
